GB granted SPC for Galliprant® on October 24, 2022, a veterinary drug productdeveloped and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until February 28, 2031. The grant in GB marks the nineth approval in the EU, following grants received in Italy, Holland, Spain, Germany, France, Ireland, Greece, Poland, and GB.

Galliprant®
Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control of pain and inflammation associated with osteoarthritis in dogs. Elanco is currently marketing Galliprant® in the US and several EU countries.

Supplementary Protection Certificate (SPC)
In major countries around the world, a patent generally expires after 20 years following submission of the patent application. However, the patent exclusivity periods for pharmaceuticals may be extended for a maximum of five years in order to compensate for the time consuming and costly research and development. The SPC grant by GB for Galliprant® represents a five-year extension of the therapy’s exclusive sales period.